In summary, they showed that systemic levels of IL-6 in patients with COVID-19 were about 12 times lower than in ARDS, about 27 times lower than in patients with sepsis, and as much as 100 times lower than in CRS. This evidence concerns the gene IL6 and acute respiratory distress syndrome.